Key facts
- This page summarizes Linda Shapiro Manning's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 11 Feb 2022, 20:34.
Linda Shapiro Manning - 09 Feb 2022 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- RYTM
- Reported as of
- 09 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Feb 2022, 20:34:18 UTC
- Prior SEC filing
- 15 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Hunter Smith, Attorney-in-Fact for Linda Shapiro Manning
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Linda Shapiro Manning filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 11 Feb 2022.
Change
- Previous filing in this sequence was filed on 15 Sep 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RYTM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 09 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $6.80
- Footnotes
- F1
RYTM
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +12,500
- Change %
- Price
- $0.000000
- Shares after
- 12,500
- Date
- 09 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,500
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
Footnote F3
The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date.